Gamble J R, Vadas M A
Division of Human Immunology, Institute of Medical and Veterinary Science, Adelaide, South Australia.
J Immunol. 1991 Feb 15;146(4):1149-54.
Recombinant human transforming growth factor-beta (TGF-beta) was found to inhibit the adhesive phenotype of human umbilical vein endothelial cells for human PBL, purified T lymphocytes, and PHA-activated lymphoblasts. TGF-beta inhibited lymphocyte attachment to resting human umbilical vein endothelial cells and also to endothelial monolayers stimulated with the pro-inflammatory cytokines TNF-alpha and IL-1 beta. Our investigations also show that the ability of endothelial cells to respond to TGF-beta by altering their adhesiveness is lost with prolonged culture of the cells. However, this loss is selective as TGF-beta inhibits cell proliferation in both early and late passage endothelial cells. These results suggest that in vivo TGF-beta may inhibit the adhesive phenotype of endothelial cells and also may limit the immunologic response occurring at the endothelial cell barrier.
重组人转化生长因子-β(TGF-β)被发现可抑制人脐静脉内皮细胞对人外周血淋巴细胞、纯化的T淋巴细胞和PHA激活的淋巴母细胞的黏附表型。TGF-β抑制淋巴细胞与静息的人脐静脉内皮细胞以及经促炎细胞因子TNF-α和IL-1β刺激的内皮细胞单层的附着。我们的研究还表明,随着细胞长时间培养,内皮细胞通过改变其黏附性对TGF-β作出反应的能力会丧失。然而,这种丧失具有选择性,因为TGF-β在早期和晚期传代的内皮细胞中均抑制细胞增殖。这些结果表明,在体内TGF-β可能抑制内皮细胞的黏附表型,并且还可能限制在内皮细胞屏障处发生的免疫反应。